SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is facing intense scrutiny and volatility as the market reacts to the President's shifting rhetoric regarding a potential military pause in Iran. Community sentiment is deeply polarized, with critics pointing to portfolio losses and questioning the company's financial fundamentals, while supporters remain vocal about their backing of the administration's aggressive policy maneuvers.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing a significant sell-off driven by unfavorable court rulings in addiction-related lawsuits, which has triggered fears of widespread litigation and regulatory headwinds. While the company's fundamentals remain a focal point for many traders, the community is currently locked in a heated debate over whether this price action represents a temporary overreaction and buying opportunity or a deeper structural shift for the stock.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing high volatility and heavy trading volume as investors debate the impact of new AI-driven tools on its long-term moat, while the company explores a potential sale of its China business to streamline operations and bolster its balance sheet. The community remains deeply divided, with bulls pointing to the growth potential of the Vector ad platform and future AI product reveals, while others express frustration over the stock's persistent decline and the competitive pressure from emerging AI-integrated workflows.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy is trending following the completion of its business combination and the appointment of former TD Ameritrade CEO Joe Moglia as an Executive Advisor. Community members are actively speculating on the stock's potential, fueled by reports of significant oil reserves in Greenland and high-profile partnerships, leading to heavy discussion regarding the company's long-term strategic value.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is trending as the community rallies around its high-profile partnership with Franklin Templeton to bring tokenized ETFs onto the blockchain. Investors are actively discussing the project's potential to bridge traditional finance with decentralized markets, fueling widespread optimism about its long-term growth and utility.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending following strong momentum in Rezdiffra prescriptions and ongoing M&A speculation, with investors closely watching the company's ability to maintain its market-leading position in the MASH space. The community is actively debating the stock's valuation as a potential buyout candidate versus the long-term growth potential of its expanding pipeline and combination therapy strategy.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is currently trending as investors debate the sustainability of its high-yield option income strategy against ongoing NAV erosion. While some in the community highlight its role as a cashflow engine in a diversified portfolio, critics continue to emphasize concerns regarding reverse splits and long-term capital preservation.

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp

GeneDx is experiencing significant volatility and intense community debate following a sharp price decline despite reporting strong revenue growth and raised guidance. Investors are actively discussing whether the sell-off presents a long-term accumulation opportunity or a signal of deeper structural concerns regarding company financials and insider activity.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened volatility as community discourse centers on Cathie Wood's aggressive rebalancing, including recent divestments from tech giants like Meta and Tesla. Investors are actively debating whether these tactical shifts signal a pivot to better risk management or a lack of conviction, while others view the current price compression at key technical support levels as a potential entry point for long-term growth exposure.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor interest as the community focuses on its aggressive commercial expansion and the upcoming CVS formulary shift, which is expected to catalyze Vevye's growth. Enthusiastic shareholders are actively tracking sales force hiring and product launch timelines, with many viewing the stock as a prime opportunity for long-term growth as the company shifts toward a more mature, cash-generating phase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers shifts business model after Novo deal

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share.But the story's changing.After the company's Novo Nordisk (NVO) deal and...

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

Equity

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 


Best Pharmaceutical Stocks To Watch Today - March 26th

Eli Lilly and Company, Terns Pharmaceuticals, and Novo Nordisk A/S are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and re...

Top Medical Stocks To Follow Now - March 26th

Eli Lilly and Company, UnitedHealth Group, Terns Pharmaceuticals, Johnson & Johnson, Novo Nordisk A/S, Cencora, and Boston Scientific are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies that develop, manu...

What's Happening With Novo Nordisk Stock Today?

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA approved GLP 1 medications, including...

<ul class="summary-bullets"><li>Wegovy will be initially available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, with a higher 7.2 mg dose to be available later, HIMS said.</li><li>Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses.</li><li>HIMS will also introduce a weight-loss membership starting at $39 for the first month, then $149 per month thereafter.</li></ul>Hims &amp; Hers Health Inc (HIMS) grabbed retail attention on Thursday after launching a broad lineup of Novo Nordisk GLP-1 medications on its platform, including the FDA-approved Wegovy pill. The rollout comes just weeks after Novo dropped its patent infringement lawsuit against Hims related to its blockbuster weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> was down more than 3%, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed nearly 2% higher at the time of writing.<h2 class="st-heading-2">Wegovy To Be Available In Several Doses</h2>HIMS said that eligible patients will have access to multiple treatment options, including Wegovy in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, and 1.5 mg, 4 mg, 9 mg, and 25 mg pill forms. A 7.2 mg injection will be available later, the company said.Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses for the management of Type 2 diabetes. It has not been approved by the FDA for weight loss.HIMS is introducing a new&nbsp;weight-loss&nbsp;membership that provides comprehensive support, including 24/7 access to healthcare providers, personalized nutrition guidance, regular check-ins, and a peer support community. Membership will start at $39 for the first month, followed by $149 per month thereafter.<h2 class="st-heading-2">Legal Battle Over Compounded Drugs</h2>Last month, Novo Nordisk filed a patent infringement lawsuit against Hims &amp; Hers after the telehealth company introduced a low-cost, compounded version of the Wegovy pill for $49 per month, claiming it contained the same active ingredient as the branded drug. Novo argued that the products violated its patents and misled consumers about safety and effectiveness, prompting the FDA to warn about the use of GLP-1 ingredients in unapproved compounded drugs.However, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> the lawsuit earlier this month and instead formed a partnership with Hims &amp; Hers, allowing the company to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices. Hims &amp; Hers also announced it would stop marketing compounded GLP-1 drugs and transition existing patients to FDA-approved treatments.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for both HIMS and NVO remained in the ‘bearish’ territory over the past 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/HIMS_jpg_50a2aae200.webp" alt="HIMS.jpg" width="855" height="94"><figcaption>HIMS' Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_c11986072f.webp" alt="NVO.jpg" width="862" height="102"><figcaption>NVO's Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure>One user said they were going long after the news came out.<stembedurl>https://stocktwits.com/turnaroundtuesdays01/message/648651986</stembedurl>Year-to-date, HIMS stock has declined by about 37%, while NVO stock has fallen by about 29%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-anktiva-trial-update-bladder-cancer-phase-2-idmc/cZ3rwRfRIjw">ImmunityBio Says Phase 2 Bladder Cancer Trial Has ‘Statistical Power’ – Anktiva-BCG Advances Toward Filing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform

Eligible patients will be able to access multiple treatment options, including Wegovy in several injection doses and pill forms, as well as Ozempic injection pens.

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Wolfe Research Begins Coverage on Novo Nordisk A/S (NYSE:NVO)

Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday. They issued a "peer perform" rating for the company...

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

ALT Pemvidutide Explained: What Makes It Different in MASH

Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S